NeoGenomics NEO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 43.2%-0.1pp | 43.2%-0.2pp | 43.5%-0.5pp | 43.9%-0.4pp | 44.3%+0.4pp | |
| Operating margin | -14.2%+1.7pp | -15.9%+1.1pp | -17%-0.4pp | -16.7%-3.4pp | -13.3%+0.7pp | |
| Net margin | -13.3%+1.6pp | -14.9%+1.1pp | -16%-0.9pp | -15.1%-3.6pp | -11.5%+0.4pp | |
| Returns | ||||||
| Return on equity | -11.6%+0.9pp | -12.4%+0.6pp | -13%-1.2pp | -11.8%-3.2pp | -8.6%0.0pp | |
| Return on invested capital | -15.7%-0.7pp | -15%+2.8pp | -17.8%-1.4pp | -16.5%-2.3pp | -14.1%-1.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.4×+0.2× | 4.3×+0.4× | 3.9×0.0× | 3.9×+1.9× | 2.1×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.2× | |
| Per Share | ||||||
| Book value per share | $6.42-1.8% | $6.530.0% | $6.53-2.2% | $6.67-4.3% | $6.97-2.1% | |
| Valuation | ||||||
| Market capitalization | $1.68B+86.5% | $1.52B+52.6% | $997.26M+7.2% | $930.46M-23.7% | $1.22B-42.4% | |
| Price / sales | 2.3×+0.9× | 2.1×+0.7× | 1.4×+0.1× | 1.4×-0.5× | 1.8×-1.4× | |
| Price / book | 2×+1.0× | 1.8×+0.6× | 1.2×+0.1× | 1.1×-0.3× | 1.4×-1.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NeoGenomics's profit margins?
- NeoGenomics (NEO) runs a 43.2% gross margin and a -14.2% operating margin, with a -13.3% net margin.
- Where do NeoGenomics's ratios come from?
- Every ratio is computed from NeoGenomics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
